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Oxidative stress is a critical disease modifier in the muscular dystrophies. Recently, we
discovered a pathway by which mechanical stretch activates NADPH Oxidase 2 (Nox2)
dependent ROS generation (X-ROS). Our work in dystrophic skeletal muscle revealed
that X-ROS is excessive in dystrophin-deficient (mdx) skeletal muscle and contributes
to muscle injury susceptibility, a hallmark of the dystrophic process. We also observed
widespread alterations in the expression of genes associated with the X-ROS pathway
and redox homeostasis in muscles from both Duchenne muscular dystrophy patients and
mdx mice. As nuclear factor erythroid 2-related factor 2 (Nrf2) plays an essential role in
the transcriptional regulation of genes involved in redox homeostasis, we hypothesized
that Nrf2 deficiency may contribute to enhanced X-ROS signaling by reducing redox
buffering. To directly test the effect of diminished Nrf2 activity, Nrf2 was genetically
silenced in the A/J model of dysferlinopathy—a model with a mild histopathologic
and functional phenotype. Nrf2-deficient A/J mice exhibited significant muscle-specific
functional deficits, histopathologic abnormalities, and dramatically enhanced X-ROS
compared to control A/J and WT mice, both with functional Nrf2. Having identified that
reduced Nrf2 activity is a negative disease modifier, we propose that strategies targeting
Nrf2 activation may address the generalized reduction in redox homeostasis to halt or slow
dystrophic progression.
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INTRODUCTION
In dystrophin-deficient heart and skeletal muscle, we recently
identified that NADPH oxidase 2 (Nox2) dependent reactive
oxygen species (ROS) production (i.e., X-ROS) is dramatically
enhanced with stretch or contraction and contributes to the
enhanced susceptibility to injury (Prosser et al., 2011; Khairallah
et al., 2012). Furthermore, we demonstrated that this enhanced X-
ROS is temporally progressive as X-ROS is virtually non-existent
in young (∼8 week) and in great excess in mature adult (∼7
month) dystrophic animals.
Limb girdle muscular dystrophy type 2B (LGMD2B), Miyoshi
myopathy, and distal myopathy are progressive, late-onset dys-
trophies linked to mutations in, or loss of, the dysferlin protein
that present clinically as weakness in the proximal or distal
muscles with elevated serum creatine kinase (CK) and muscle
degeneration (Nigro, 2003; Klinge et al., 2008; Amato and Brown,
2011). We reported that aged (∼12 month) dysferlin-deficient
murine muscle also exhibits amplified X-ROS signaling (Prosser
et al., 2013), a finding congruent with the recent reports suggest-
ing that oxidative stress underscores the late onset and temporal
progression of dysferlinopathy (Terrill et al., 2013). Despite these
findings, it is unclear what manifests the age-dependent increase
in X-ROS in these dystrophic models.
Within the healthy muscle cell, ROS are generated as both
a by-product of metabolism and as effectors of signaling cas-
cades. Excess ROS is counteracted by proteins that promote
reduction-oxidation (i.e., redox) chemistry under normal con-
ditions. Our recent work identified a down-regulation in the
transcriptional profile of redox related genes in murine adult
dystrophin-deficient (mdx) tibialis anterior muscle (Khairallah
et al., 2012), suggesting that a decrease in redox related proteins
may induce a shift to a more oxidized environment and drive
dysfunction in dystrophic muscle.
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a tran-
scription factor ubiquitously expressed in most tissues, but most
abundantly in kidney, striated muscle, and lung. Nrf2 is bound to
Kelch like-ECH-associated protein 1 (Keap1) in the cytosol. In
response to oxidative stress, the Nrf2–Keap1 interaction is dis-
rupted and Nrf2 translocates into the nucleus where it activates
the Antioxidant Response Element (ARE) which transcriptionally
activates many antioxidative genes. In this role, Nrf2 activity has
been demonstrated to be an important disease modifier in many
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oxidative/inflammatory diseases, such as asthma, sepsis, cerebral
hemorrhage, and pulmonary fibrosis, where decreased Nrf2 activ-
ity exacerbates disease progression (Cho et al., 2004; Rangasamy
et al., 2005; Thimmulappa et al., 2006; Wang et al., 2007).
As we recently identified amplified X-ROS signaling in aged
dysferlin-deficient A/J mice (Prosser et al., 2013) and others
have now reported a temporal progression in muscle oxidation
in dysferlin-deficient muscle (Terrill et al., 2013), we sought to
directly test the hypothesis that a decrease in Nrf2 activity could
serve as a disease modifier in dystrophic muscle. To this end we
genetically silenced Nrf2 in the A/J mouse model of dysferlinopa-
thy. We chose this model as it is considered a relatively weak
model of dysferlinopathy due to its lack of significant functional
deficits and mild, late onset, histological presentation (Von der
Hagen et al., 2005; Kobayashi et al., 2010; Gayathri et al., 2011;
Grounds and Shavlakadze, 2011; Kobayashi et al., 2011; Terrill
et al., 2013). Examination of A/J-Nrf2−/− muscle at 12 months
of age revealed a dramatic enhancement in X-ROS, significant
decreases inmuscle function, and histological evidence of myopa-
thy. Taken together, these results support decreased Nrf2 activity
as a disease modifier in dysferlinopathy.
MATERIALS AND METHODS
MICE
Dysferlin-null A/J mice were obtained from Jackson Laboratories
and bred in our facility. A mouse model of dysferlinopathy
with ablated Nrf2 (A/J-Nrf2−/−) was obtained by backcrossing
Nrf2−/− mice (C57BL/6J background) 7 times with A/J mice. All
experimental protocols conducted on the mice were performed
in accordance with NIH guidelines and were approved by the
Johns Hopkins University and University of Maryland, Baltimore
Animal Care and Use Committees.
ISOLATION OF FLEXOR DIGITORIS BREVIS (FDB) MYOFIBERS
After euthanasia by CO2 inhalation, the FDB muscle was har-
vested bilaterally and incubated in Dulbecco’s Modified Eagle’s
Medium (DMEM; Life Technologies, Grand Island, NY, USA)
with 1μl/ml gentamicin and 4mg/ml collagenase A (Roche
Applied Science, Indianapolis, IN, USA) for up to 3 h as previ-
ously described (Ziman et al., 2010; Dorsey et al., 2012). Single
intact myofibers were then isolated by gentle trituration.
MYOFIBER ATTACHMENT AND STRETCH
All experiments were performed as described (Khairallah et al.,
2012). In brief, we used a custom rotating glass-bottom cham-
ber (Four-hour Day Foundation, Towson, MD, USA) equipped
with bath perfusion and mounted on Zeiss Radiance fluorescent
laser scanning confocal attached to an Olympus IX-70 inverted
microscope (Olympus Corp., Centre Valley, PA, USA). A high-
sensitivity force transducer (KG7) and length controller (World
Precision Instruments, Sarasota, FL, USA) were mounted on
folded motorized micromanipulators (Siskiyou, Grants Pass, OR,
USA). A single FDB fiber was attached to both the force trans-
ducer and the length controller using micro-tweezers coated with
the biological adhesive, MyoTak (Ionoptix, Milton, MA, USA).
Using a high-speed video sarcomere length system (HSVL; Aurora
Scientific, Aurora, Ontario, Canada), initial sarcomere length and
sarcomere length following passive stretch were monitored. To
induce X-ROS, FDB fibers were challenged with a brief 5 s passive
stretch (10% sarcomere length).
REACTIVE OXYGEN SPECIES (ROS) MEASUREMENTS
ROS was measured as previously described (Prosser et al.,
2011) using 6-carboxy-2′,7′-dichlorodihydrofluorescein diacetate
(DCFH-DA, or DCF) (Invitrogen, Carlsbad, CA, USA) in
dimethyl sulfoxide (DMSO). FDB fibers were suspended in
HEPES-buffered Ringer’s solution containing (inmM): 140 NaCl,
4 KCl, 1 MgSO4, 5 NaHCO3, 10 glucose, 10 HEPES at pH 7.3 and
incubated with Ringer’s solution containing DCFH-DA (10μM)
for 30min at room temperature (22◦C). DCFH-DA-loaded
cells were imaged using confocal line-scanning microscopy at
2ms/line with the lowest laser power possible that reported a
stretch dependent ROS signal. DCFH-DA fluorescence signals
were processed as previously described (Prosser et al., 2011).
WESTERN BLOTTING
Western blot analysis was performed as previously described
(Dorsey et al., 2012). Briefly, 20μg of clarified muscle extract
was subjected to SDS-PAGE, transferred to nitrocellulose mem-
branes and blocked in a 5% milk solution in PBS for 1 h.
The membrane was probed overnight with primary antibody
at room temperature. The primary antibodies were anti-α-
tubulin (DM1A, 1:1000; Sigma-Aldrich), anti-β-tubulin (AA12.1,
1:1000, Developmental Studies Hybridoma Bank), anti-Glu-
tubulin (1:1000, Millipore, Temecula, CA, USA), anti-gp91phox
(1:1000, BD Transduction Laboratories, Lexington, KY, USA),
and anti-GAPDH (1:4000, Millipore). Membranes were washed
twice for 10min in 5% milk solution at room temperature, then
incubated with appropriate secondary antibody (1:10,000) for 1 h
at room temperature and washed in a 0.5%Tween solution in PBS
twice for 10min. Immunoblots were developed using SuperSignal
PicoWest chemiluminescence (Pierce, Rockford, IL, USA) and
were imaged and quantified with a SYNGENE GBox imaging sys-
tem (GeneTools software). GAPDH served as a loading control.
IN VIVO ASSESSMENT OF QUADRICEPS FORCE
Functional assessment of the quadriceps muscle was performed
in vivo as described (Pratt et al., 2012). Mice were deeply anes-
thetized with isoflurane and placed in a supine position on the
apparatus. The thigh was stabilized and the ankle secured onto
a lever arm with the rotational axis of the knee aligned with the
axis of the stepper motor/torque sensor. The femoral nerve was
stimulated via subcutaneous needle determined by a series of iso-
metric twitches and by observing isolated knee extension in the
anesthetized animal. Maximal torque was assessed as the mean of
3 successive (1min apart) maximal tetanic contractions (1 s train,
0.2μs sq pulses, 100Hz).
IN VITRO MUSCLE CONTRACTILITY
Muscle performance of the extensor digitorum longus (EDL) was
assessed in vitro using methods described previously (Williams
et al., 1998). In brief, single EDL muscles were surgically excised
with ligatures at each tendon (5-0 silk suture) and mounted in an
in vitro bath between a fixed post and force transducer (Aurora
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300B-LR) operated in isometric mode. The muscle was main-
tained in physiological saline solution (PSS; pH 7.6) containing
(in mM) 119 NaCl, 5 KCl, 1 MgSO4, 5 NaHCO3, 1.25 CaCl2,
1 KH2PO4, 10 HEPES, 10 dextrose, and maintained at 30◦C
under aeration with 95 O2/5 CO2 (%) throughout the experi-
ment. Resting tension and stimulation current were iteratively
adjusted for each muscle to obtain optimal twitch force. During a
5min equilibration, single twitches were elicited at every 30 s with
electrical pulses (0.2ms) via platinum electrodes running parallel
to the muscle. Optimal resting tension was determined and iso-
metric tension was evaluated by 250ms trains of pulses delivered
at 1, 10, 20, 40, 60, 80, 100, 150Hz. After the experimental pro-
tocol, the muscle rested for 5min at which time muscle length
was determined with a digital micrometer, muscle was trimmed
proximal to the suture connections, blotted and weighed. The
cross-sectional area for each muscle was determined by dividing
the mass of the muscle (g) by the product of its length (Lo, mm)
and the density of muscle [1.06 g/cm3; (Mendez and Keys, 1960)]
and was expressed in square centimeters. Muscle output was then
expressed as isometric tension (g/cm2) determined by dividing
the tension (g) by themuscle cross-sectional area.Maximal torque
was assessed as the mean of 3 successive (1min apart) maximal
tetanic contractions (1 s train, 0.2μs sq pulses, 100Hz).
HISTOPATHOLOGY
Quadriceps muscles were fixed in 10% formalin and flash frozen.
Cross-sections (5μm) were obtained from the mid-belly of
the muscle. H&E staining was performed to qualitatively assess
inflammatory cell infiltrate and centrally nucleated fibers (CNFs).
Picrosirius red staining was used to assess collagen and fibrosis.
Digital images (20× magnification) were obtained and the area
of rectus femoris was calculated using ImageJ (National Institutes
of Health, Bethesda, MD). CNFs were quantified from images
(100× magnification) taken at the lesion in the rectus femoris
from each genotype. ImageJ was used to calculate the total area
of fat accumulation (vacuolated area).
IMMUNOHISTOCHEMISTRY OF OXIDIZED PHOSPHOLIPIDS
Muscle sections of 5μm thickness were generated from for-
malin fixed quadriceps were stained with antibodies generated
against oxidized phospholipids (oxPL) to assess oxPL and oxida-
tive stress. Staining was done according to the manufacturer’s
protocol (Dako). Digital images (20× magnification) were at the
same location in the muscle from each genotype.
STATISTICS
Statistical comparisons were performed using Student’s t-test or
One-Way ANOVA (SigmaStat v3.1) with significance set a priori
to 0.05.
RESULTS
STRETCH-INDUCED ROS GENERATION IS EXAGGERATED IN THE
Nrf2-SILENCED DYSFERLIN DEFICIENT MUSCLE
We recently reported on X-ROS, a signaling pathway by which
mechanical stretch elicits Nox2 ROS signaling in heart and skele-
tal muscle (Prosser et al., 2011; Khairallah et al., 2012). The
microtubule (MT) cytoskeleton is the mechano-transduction
element that transmits the strain of stretch or contraction to
Nox2, and hence, is critical for the generation of X-ROS. We
further identified excess X-ROS magnitude and enhanced X-
ROS protein expression (i.e., MT and Nox2 protein subunits)
in dystrophin-deficient heart and skeletal muscle. In each tissue,
the increased magnitude of X-ROS contributed to dysfunctional
ROS, alterations in calcium signaling, and injury susceptibil-
ity. Integral to this current work, we most recently identified
enhanced X-ROS and increased X-ROS-related protein expres-
sion in the A/J model of dysferlinopathy (Prosser et al., 2013).
Here we used an identical approach to assess the rate of ROS
production in single isolated FDB myofibers from A/J-Nrf2−/−
mice loaded with DCF and challenged with an acute stretch of
a 10% change in sarcomere length. In FDBs from 12-month
dysferlin-deficient A/J mice, we confirmed a significant increase
in X-ROS compared to WT controls. We found that in dysferlin-
deficient FDBs with genetically silenced Nrf2, the X-ROS rate was
significantly elevated above that seen in the dysferlin-deficient
A/J (Figures 1A,B). This result suggests that a decrease in Nrf2
activity accelerated the temporal manifestation of X-ROS in the
dysferlin-deficient A/J model.
Western blot analysis revealed that Nrf2 silencing in the
A/J resulted in the increased expression of X-ROS-related pro-
teins, including α- and β-tubulin, glu-tubulin, and gp91phox
(Figure 2A), consistent with the increased magnitude of X-ROS
we demonstrated in this model. Importantly, the silencing of Nrf2
alone (i.e., Nrf2−/−) did not result in an increased expression of
these proteins, indicating that Nrf2 silencing in the dystrophic
(A/J-Nrf2−/−) model drove this response (Figure 2B).
MUSCLE FUNCTION AND QUALITY IS DECREASED IN THE
Nrf2-SILENCED DYSFERLIN DEFICIENT MOUSE
We have proposed that excessive X-ROS signaling is a proximal
mechanism for themuscle damage and force deficits in dystrophic
muscle. To assess the effect of Nrf2 silencing on the dysferlin-
deficient A/J, we first evaluated nerve-evoked muscle function
FIGURE 1 | X-ROS is enhanced in Nrf2 silenced dysferlin deficient
muscle fibers. FDB fibers from WT (n = 3animals, 8fibers), dysferlin deficient
A/J (n = 3animals, 9fibers), and Nrf2-silenced A/J (n = 3animals, 11fibers) were
loaded with the fluorescent ROS probe DCF and attached with MyoTak
between a high-sensitivity force transducer and length controller. The fibers
were challenged with a brief 5 s passive stretch (∼10% sarcomere length)
and DCF fluorescence signals (A) were processed as previously described
(Prosser et al., 2011). The DCF fluorescent rate, expressed as a % over the
pre-stretch condition, revealed that WT stretch was not different from the
pre-stretch condition, dysferlin deficient A/J was significantly elevated over
WT, and Nrf2 silenced A/J were elevated compared to each other genotype.
The population averages are represented in the bar graph in (B). ∗p < 0.05.
www.frontiersin.org February 2014 | Volume 5 | Article 57 | 3
Kombairaju et al. Nrf2-deficiency amplifies X-ROS signaling
FIGURE 2 | X-ROS protein expression is elevated in Nrf2 silenced
dysferlin deficient muscle. Western blot analysis of gastrocnemius muscle
from 1 year old mice identified that X-ROS protein content is significantly
elevated in Nrf2 silenced A/J muscle (A) (n = 5) but not in Nrf2 silenced
muscle (B) (n = 5). Percent changes in protein expression are demonstrated
in the bar graphs to the right of both (A,B). ∗p < 0.05.
FIGURE 3 | Nrf2 silenced A/J muscle exhibits a loss-of-function
phenotype. (A) In vivo assessments of isomeric quadriceps torque and
(B) in vitro assessments of EDL contractility via the force vs. stimulation
frequency relationship both revealed significant loss-of-function phenotypes
in the Nrf2 silenced dysferlin deficit A/J muscle. ∗p < 0.05.
in vivo. Evaluation of quadriceps muscle function revealed a sig-
nificant deficit in maximal isometric torque in the A/J-Nrf2−/−
vs. the A/J (Figure 3A) despite no difference in bodyweight (27.2
± 2.1 vs. 28.4 ± 1.9 g). To assess muscle specific force pro-
duction, we analyzed electrically evoked contractions in single
EDL muscles in vitro. An examination of the force (normal-
ized to the muscle cross-sectional area) vs. stimulation frequency
relationship revealed a significant deficit in force producing
capacity in the A/J-Nrf2−/− (Figure 3B). Histological analysis
of the quadriceps muscles provided insight for the deficits in
muscle function following Nrf2 ablation, as A/J-Nrf2−/− mice
exhibit enhanced degeneration compared to A/J mice (Figure 4).
Furthermore, these muscles present with increased immune cell
infiltrate (Figure 4A; top, right), fibrosis (Figure 4A; bottom,
right), steatosis (fat accumulation), and a concomitant decrease
in total myofiber area in cross-section (Figure 4B). Taken together
FIGURE 4 | Histological evidence of enhanced pathology in Nrf2
silenced A/J muscle. (A) Cryosections were H&E stained to evaluate
myofiber morphology and immune cell infiltrate (top) and Picrosirius red
stained for assaying collagen content (bottom). (B) The Nrf2 silenced A/J
muscle exhibited a decrease in total myofiber area, an increase in collagen
content, the number of CNFs, and fatty deposits. ∗p < 0.05.
with the increase in the occurrence of CNFs and evidence
of increased oxidative stress (Figure 5), we conclude that the
A/J-Nrf2−/− mouse presents with a significantly enhanced dys-
trophic phenotype compared to age-matched A/J mice.
Frontiers in Physiology | Striated Muscle Physiology February 2014 | Volume 5 | Article 57 | 4
Kombairaju et al. Nrf2-deficiency amplifies X-ROS signaling
FIGURE 5 | Increased oxidative stress in of Nrf2 silenced A/J
quadriceps muscle. Quadriceps muscles (n = 6) were isolated from A/J
and A/J-Nrf2−/− mice at 1 year of age, and were stained with antibodies
against oxPL. Sections from A/J-Nrf2−/− muscles (right panels) exhibit
excess oxPL (dark brown staining), compared to sections derived from A/J
mice (left panels).
DISCUSSION
LGMD2B, Miyoshi myopathy, and distal myopathy are pro-
gressive dystrophies that present clinically as weakness in the
proximal or distal muscles with elevated serum CK and muscle
degeneration (Nigro, 2003; Klinge et al., 2008; Amato and Brown,
2011). These diseases are established as late-adult onset both clin-
ically (Gordon et al., 1993; Klinge et al., 2008; Angelini et al., 2010,
2011; Gayathri et al., 2011) as well as in preclinical models (Turk
et al., 2006; Nemoto et al., 2007; Ng et al., 2012). While these
disorders have been linked to the mutation or ablation of the dys-
ferlin gene (DYSF) (Illarioshkin et al., 2000; Vainzof et al., 2001;
Nguyen et al., 2005; Cacciottolo et al., 2011), a consensus on the
mechanistic basis of disease has not been reached.
Early functional studies in murine muscle (Bansal et al., 2003;
Bansal and Campbell, 2004) implicated dysferlin as an inte-
gral component for rapid repair of the sarcolemma. However,
more recent reports indicate that dysferlin is also involved in
vesicle fusion, cellular adhesion, MT regulation and the sta-
bilization of sarcolemmal/transverse-tubule Ca2+ homeostasis
(Lennon et al., 2003; Covian-Nares et al., 2010; Sharma et al.,
2010; Di Fulvio et al., 2011; De Morree et al., 2013; Kerr
et al., 2013). Most recently, evidence points to an age-dependent
enhancement in oxidative stress in dysferlin-deficient muscle
(Prosser et al., 2013; Terrill et al., 2013) leading us to speculate
that a progressive enhancement in oxidative stress may tempo-
rally associate with the late onset of muscle pathology seen in
dysferlinopathy.
We previously identified a decrease in redox related genes
in Dmd muscle (Khairallah et al., 2012), and have identified
similar profiles from interrogating publically available microarray
data from clinical biopsy samples of dysferlinopathic individu-
als (GEO repository; data not shown). Together, the increased
lipid peroxidation in muscles of dysferlinopathy patients (Renjini
et al., 2012), the progressive oxidation of muscle of dysferlin defi-
cient A/J mice (Terrill et al., 2013), and the increase in X-ROS
in dysferlin-deficient muscle (Prosser et al., 2013) all indirectly
support a decline in Nrf2 activity as a factor in the onset and
pathogenic progression of the disease. In further support of Nrf2’s
role, a decline in Nrf2 activity, increased oxidative stress and
reduced antioxidant defense seem to be general phenomena in
chronic diseases and aging (Malhotra et al., 2008; Safdar et al.,
2010; Sykiotis and Bohmann, 2010), therefore it will be impor-
tant to also evaluate the effect of Nrf2 silencing in the context of
aging WT muscle, a comparison not made in this study.
Our sentinel measure of stretch activated X-ROS was previ-
ously shown to be elevated in the dysferlin-deficient A/J mouse,
and here we demonstrate a dramatic (>2-fold) elevation in X-
ROS in A/J-Nrf2−/− muscle compared to the A/J (c.f. Figure 1).
As discussed above, ROS production is countered by the endoge-
nous cellular redox buffering systems such that a detectable
increase in ROS production could be due to an increase in
ROS production via more ROS producing sources (i.e., Nox2 or
mitochondrial metabolism), a decrease in redox buffering, or a
combination of both. Interestingly, the silencing of Nrf2 in the
A/J resulted in an increase in X-ROS proteins (α-, β-tubulin
and gp91phox), which may suggest a more complex interplay of
redox homeostasis and the transcriptional regulation of these X-
ROS-related proteins. Presently, pharmacological approaches that
target single redox or ROS pathways (N-acetylcysteine, EGCG,
Tocopherol) have shownmixed results in reducing the pathogenic
progression of the muscular dystrophies (Scheuerbrandt, 2008),
though combinatorial approaches may have better outcomes
(Potgieter et al., 2011). In other diseases, genetic or pharmaco-
logical activation of Nrf2 has been shown to reduce oxidative
and nitrosative stress and provide significant functional bene-
fit (Thimmulappa et al., 2007; Sussan et al., 2009; Blake et al.,
2010). Our results support a centralized role of Nrf2 deficiency
in the pathogenesis of dysferlinopathy. We hypothesize that
strategies targeting Nrf2 activation may ablate the core mech-
anistic hallmarks of dysferlinopathic progression (i.e., oxidative
stress, inflammation, fibrosis, lipid accumulation). Further, as
most muscular dystrophies share these mechanistic underpin-
nings, this approach, if successful, may have wide therapeutic
applications.
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